P004 Morphoea in a patient with clear cell renal cancer and lung metastases

George Palaiologos,Anastasios Mavrogiorgos
DOI: https://doi.org/10.1093/bjd/ljae090.031
IF: 11.113
2024-06-28
British Journal of Dermatology
Abstract:Abstract Morphoea (localized scleroderma) is an autoimmune fibrotic skin disease with an estimated prevalence of 200 per 100 000. Although the pathogenesis remains unknown, the disease is characterized by an initial T-cell-mediated inflammatory phase followed by localized fibrosis of the skin. Most cases of morphoea in patients with cancer occur after radiation therapy (65%), chemotherapy (8.5%) or immunotherapy–immune checkpoint inhibitor (ICI) therapy (5.7%). In two-thirds of cases of morphoea in patients with cancer, the mean time to onset of morphoea is 3.2 years after radiation, 1.7 years after chemotherapy, and 8 months (rapid manifestation of morphoea) after ICI immunotherapy. We present the case of a 65-year-old male patient with a history of clear cell renal carcinoma, who underwent surgical removal of his right kidney 5 years previously. Two years postoperatively, he developed a metastatic nodule in the right upper lobule of his lung. The patient was under treatment with pazopanib 800 mg per day for 15 months. Pazopanib is a tyrosine kinase inhibitor that blocks tumour growth and inhibits angiogenesis. The metastatic nodule disappeared but a new one appeared (computed tomography and magnetic resonance imaging). While the second metastasis remained stable and the patient was not undergoing any treatment, he developed the typical skin lesions of morphoea, with numerous sclerotic, or atrophic lesions with lilac ring, 2.5 years after the cessation of pazopanib. The diagnosis was confirmed by biopsy and he is currently under topical treatment with cortisone and calcineurin inhibitors. To date, several studies have reported sudden development of morphoea either before or after a brief interval following the diagnosis of malignancy. Scleroderma is characterized by immunological dysregulation, vasculopathy and hyperproduction of the extracellular matrix by activated fibroblasts. Endothelial inflammatory and mesenchymal cells produce cytokines, growth factors (interleukins 1 and 6 and tumour necrosis factor-α), connective tissue growth factor, and basic fibroblast growth factor. In our case study, we examined a patient with a localized type of scleroderma (morphoea) without confirming the markers for systemic involvement. Morphoea developed 5 years after the diagnosis of clear renal cell carcinoma and 2.5 years after the cessation of pazopanib – a tyrosine kinase inhibitor – so it should be considered a paraneoplastic phenomenon rather than a secondary effect of pazopanib cancer therapy.
dermatology
What problem does this paper attempt to address?